Benchmark Reaffirms Buy Rating for BlueLinx (NYSE:BXC)
BlueLinx (NYSE:BXC – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Benchmark in a note issued to investors on Wednesday, Benzinga reports. They currently have a $135.00 target price on the construction company’s stock. Benchmark’s target price would suggest a potential upside of 30.59% from the company’s current price. BXC […]
More Stories
MediciNova, Inc. (NASDAQ:MNOV) Short Interest Up 19.3% in September
MediciNova, Inc. (NASDAQ:MNOV – Get Free Report) was the target of a significant increase in short interest in the month...
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Grows By 22.8%
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) was the target of a significant increase in short interest in September....
Merck KGaA (OTCMKTS:MKGAF) Short Interest Up 26.9% in September
Merck KGaA (OTCMKTS:MKGAF – Get Free Report) saw a large increase in short interest in the month of September. As...
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Sees Significant Growth in Short Interest
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Get Free Report) was the recipient of a large increase in short interest in the...
Two Harbors Investment Corp. (NYSE:TWO) Short Interest Up 17.5% in September
Two Harbors Investment Corp. (NYSE:TWO – Get Free Report) saw a significant increase in short interest in September. As of...
World News in Brief: Possible ‘dire consequences’ for Yemen following strikes, Ukraine hospital attack, human rights in Algeria
UN humanitarians on Monday warned of the potentially dire consequences that could arise from disruption to the flow of food...